Patents Examined by Kimberly Chong
  • Patent number: 10711274
    Abstract: The invention relates to inhibitory nucleic acids and rAAV-based compositions, methods and kits useful for treating Amyotrophic Lateral Sclerosis.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 14, 2020
    Assignee: University of Massachusetts
    Inventors: Christian Mueller, Robert H. Brown, Jr.
  • Patent number: 10709728
    Abstract: The invention relates to polynucleotide agents, e.g., antisense polynucleotide agents, targeting an angiotensinogen (AGT) gene, and methods of using such polynucleotide agents to inhibit expression of AGT and to treat subjects having an AGT-associated disease, e.g., hypertension.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: July 14, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Patent number: 10709793
    Abstract: Disclosed is a gene/carrier complex for preventing or treating inflammatory diseases, including tumor necrosis factor-? converting enzyme (TNF-? converting enzyme, TACE) shRNA and a nonviral gene carrier, wherein the nonviral gene carrier includes an acetate of disulfide-linked poly(oligo-arginine) or a TFA salt of poly(oligo-aspartic acid)poly(oligo-arginine).
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 14, 2020
    Assignees: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY, INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Yong-Hee Kim, Tae-Hwan Kim, Chul-Su Yang, Yoonsung Song, Jee-Young Chung, Sungsin Jo, So Mi Kim, Qurrat Ui Ain, Ye-Ram Kim
  • Patent number: 10711272
    Abstract: Provided herein are, inter alia, nucleic acid compounds useful for targeting CTLA-4-expressing cells and modulating cell activity of the CTLA-4-expressing cells. The compositions provided herein may be part of pharmaceutical compositions and may be used for treatment of cancer, inflammatory diseases, infectious diseases or metabolic diseases.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: July 14, 2020
    Assignee: City of Hope
    Inventors: Hua Yu, Andreas Herrmann, Marcin Tomasz Kortylewski
  • Patent number: 10695443
    Abstract: Methods for introducing nucleic acids to cells via exosomes for use in gene modulation and therapy, such as for gene silencing and to introduce genetic material into cells to compensate for abnormal genes or to induce or repress a process in the recipient cell.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: June 30, 2020
    Assignee: Codiak BioSciences, Inc.
    Inventors: Jan Lötvall, Hadi Valadi
  • Patent number: 10695341
    Abstract: Provided herein are methods of treating and/or preventing endometriosis or symptom thereof, assays for diagnosing/prognosing endometriosis, compositions and formulations for treating and/or preventing endometriosis or symptom thereof, and populations of endometiotic cells, including life-extended populations of cells.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: June 30, 2020
    Assignees: University of South Florida, Ponce Health Sciences University
    Inventors: Meera Nanjundan, Kyle A. Bauckman, Idhaliz Flores
  • Patent number: 10689648
    Abstract: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 23, 2020
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Brian Allen Carr, Vasant R. Jadhav, Denise M. Kenski, David M. Tellers, Aarron T. Willingham
  • Patent number: 10689650
    Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: June 23, 2020
    Assignees: STELIC INSTITUTE & CO., (NATIONAL UNIVERSITY CORPORATION) NIIGATA UNIVERSITY
    Inventors: Hiroyuki Yoneyama, Kenji Suzuki
  • Patent number: 10683499
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 16, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10677805
    Abstract: The invention relates to color-changing eye drops for early screening Alzheimer's disease and an application thereof. The color-changing eye drop for early screening Alzheimer's disease comprises 1 pg/ml to 10 ng/ml of A?42 aptamer-gold nanoparticles (AuNPs) and a pharmaceutically acceptable carrier or vehicle thereof, which can be used to mix with a tear sample of a test subject to analyze a color change of the color-changing eye drop for determining the concentration proportion of A?40:A?42 contained in the tear sample of the test subject.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: June 9, 2020
    Assignee: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: Jung-Chih Chen, I-Chiu Li, Kun-Che Li, Ching-Cheng Chuang, Mei-Lan Ko, Han-Chien Chuang, Ming-Hung Chien, Yu-Rong Wang, Hung-Ru Wang
  • Patent number: 10669546
    Abstract: Disclosed herein are antisense compounds and methods for decreasing SOD-1 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate SOD-1 associated diseases, disorders, and conditions. Such SOD-1 associated diseases include amyotrophic sclerosis (ALS).
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: June 2, 2020
    Assignee: Biogen MA Inc.
    Inventor: Eric E. Swayze
  • Patent number: 10662431
    Abstract: Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: May 26, 2020
    Assignee: ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE
    Inventors: John George Dickson, Jagjeet Kaur Kang
  • Patent number: 10663456
    Abstract: The present invention provides means for evaluating harmfulness of a chemical substance before occurrence of cell death, that is, more quickly and sensitively compared to conventional methods wherein the remaining viable cell count is determined using a reductive coloring reagent after a period of time required for occurrence of cell death due to the chemical substance. A double-stranded RNA probe comprising an RNA strand labeled with a fluorescent dye A that emits fluorescence, and an RNA strand labeled with a fluorescent dye B that quenches emission from a fluorescent dye in the vicinity thereof, wherein the fluorescence is quenched in a double-stranded state due to occurrence of fluorescence resonance energy transfer (FRET) between the two kinds of fluorescent dyes.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: May 26, 2020
    Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY
    Inventors: Hidenori Tani, Masaki Torimura, Hiroaki Sato
  • Patent number: 10662429
    Abstract: Embodiments herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods of use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: May 26, 2020
    Assignee: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Michael Milsom, David A. Williams, Richard Gregory
  • Patent number: 10655129
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of huntingtin in a cell, tissue or animal. Further provided are methods of slowing or preventing Huntington's Disease (HD) progression using an antisense compound targeted to huntingtin. Additionally provided are methods of delaying or preventing the onset of Huntington's Disease (HD) in an individual susceptible to Huntington's Disease (HD). Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: May 19, 2020
    Assignee: IONIS PHARMACEUTICALS, Inc.
    Inventor: Susan M. Freier
  • Patent number: 10655182
    Abstract: Disclosed herein is a method for diagnosing a renal allograft recipient's risk for developing fibrosis of the allograft and allograft loss. The method includes determining the expression levels of certain microRNAs, which have been determined to be predictive of an allograft recipient's risk. Also disclosed herein is a method of treating a renal allograft recipient to inhibit fibrosis of the allograft and allograft loss, as well as kits for use in the methods disclosed herein.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: May 19, 2020
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Murphy, Weijia Zhang
  • Patent number: 10653624
    Abstract: The present disclosure relates to a method of delivering target materials into extracellular vesicles including exposing the target materials and the extracellular vesicles to extracorporeal shockwaves, a method of preparing target material-introduced extracellular vesicles, extracellular vesicles prepared by the method, drug delivery vehicles including extracellular vesicles, and a method of delivering target materials into cells. The present disclosure exposes extracellular vesicles derived from natural organisms such as animal cells, plant cells, and microorganisms including bacteria and eukaryotic bacteria as well as artificially produced extracellular vesicles to extracorporeal shockwaves extracellularly. Thus, the high-level energy extracorporeal shockwaves can be used to deliver the target material into the extracellular vesicle efficiently. When treating with extracorporeal shockwaves, the ability of target material-introduced extracellular vesicles to incorporate into target cells also increases.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 19, 2020
    Assignee: EXOLLENCE BIOTECHNOLOGY CO., LTD.
    Inventors: Kihwan Kwon, Jihwa Chung, Kyounghwa Kim
  • Patent number: 10639399
    Abstract: Provided is a use of one or more MicroRNA genes selected from miRNAs of Family Let-7, miR-21 or miR-222 in the construction of tissue engineered nerves and in the repair of peripheral nerve defects. An outer and/or internal surface or pores of a tissue engineered nerve graft are coated or adsorbed with polymeric nanomicrospheres carrying a Let-7 family miRNA inhibitor, miR-21, or miR-222, or a mimetic thereof, wherein the polymeric material is composed of biocompatible fibronectin and heparin. The regeneration of peripheral nerves and the construction of tissue engineered nerves are promoted by regulating the expression of MicroRNA genes which can effectively promote the proliferation of primary Schwann cells cultured in vitro and have an anti-apoptotic effect on neuronal cells. In-vivo test proves that bridging of the tissue engineered nerve graft can facilitate the regeneration of peripheral nerves, thus being useful in the treatment of peripheral nerve injury.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: May 5, 2020
    Assignee: NANTONG UNIVERSITY
    Inventors: Xiaosong Gu, Fei Ding, Xin Tang, Yumin Yang, Bin Yu, Shiying Li, Songlin Zhou, Luzhong Zhang, Yaxian Wang, Yun Gu, Hualin Sun
  • Patent number: 10640768
    Abstract: The present invention provides a screening method for pain suppressors, which method is characterized by using netrin-4 and/or a netrin-4 receptor to select a substance capable of inhibiting downstream signaling from netrin-4. According to the screening method of the present invention, pain suppressors useful as a preventive or therapeutic medicine for pain can be identified. The present invention also provides a pharmaceutical composition for prevention or treatment of pain, which composition comprises, as an active ingredient, a substance capable of inhibiting downstream signaling from netrin-4.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 5, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Toshihide Yamashita, Yasufumi Hayano
  • Patent number: 10640788
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Reseach Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy